TXG

T3Russell 2000Innovation (ARKK)

10x Genomics, Inc.

Next est. report · AMC

Loading…
Loading chart…
Overview

10x Genomics develops instruments, consumables, and software for analyzing biological systems. Their Chromium platforms enable single-cell gene expression and m

10x Genomics develops instruments, consumables, and software for analyzing biological systems. Their Chromium platforms enable single-cell gene expression and multi-omics, while Visium and the new Atera platform offer advanced spatial biology insights, including whole transcriptome profiling. They serve academic, government, and biopharma researchers, with AI-driven demand increasing.

Key Inputs And Sourcing

1. Reagents / Biochemical Materials

Not in registry

component · Global, Singapore · unknown

Source Explicitly mentioned as critical for consumables and kits (e.g., 'reagent kits', 'proprietary chemistry', 'enzymes, oligonucleotides, primers, probes, buffers, and other assay reagents'). Manufacturing facility in Singapore for reagents.

Confidence: high

2. Microfluidic Chips / Slides / Plastic Consumables

Not in registry

component · Global · unknown

Source Essential for single-cell and spatial platforms (e.g., 'microfluidic chips', 'custom chips, cartridges, slides, and molded parts').

Confidence: high

3. Instrument Components (Electronics, Optics, Precision Assemblies)

Not in registry

component · Global · unknown

Source Critical for manufacturing Chromium, Xenium, and Atera instruments (e.g., 'Optics, imaging parts, electronics, precision assemblies, and other specialized hardware').

Confidence: high

4. Manufacturing Labor

Not in registry

labor · US, Singapore · unknown

Source Implied by 'lower manufacturing costs' and operation of manufacturing facilities.

Confidence: high

5. Logistics and Cold-Chain Services

Not in registry

logistics · containerized-freight-index · Global · unknown

Source 'Logistics and cold-chain providers: Some reagents and kits require careful storage and shipping conditions.'

Confidence: medium

6. Gel Beads

Not in registryaccess=api

component · Global · unknown

Source Core component of GEM technology, containing barcoded primers.

Confidence: high

7. Software Development Labor

Not in registry

labor · Global · unknown

Source 'Bioinformatics expertise required to analyze increasingly rich data sets', 'software side' for Atera, 'computational biology, software' as distinctive capabilities.

Confidence: high

8. Packaging Materials

Not in registry

packaging · Global · unknown

Source Procured from qualified suppliers.

Confidence: medium

9. Partitioning Oil

Not in registry

component · Global · unknown

Source Used in microfluidic process to create GEMs.

Confidence: medium

Industry Publications

  • GenEngNews (GEN) (genengnews.com) — Essential for tracking broader trends in genetic engineering, biotechnology, and 'omics' technologies, including new product launches and research advancements relevant to 10x Genomics' platforms. [cite: Theme_Overview]
  • Nature Biotechnology (nature.com/nbt) — A leading journal for high-impact research in biotechnology, frequently publishing advancements in single-cell and spatial biology, directly relevant to 10x Genomics' core technologies.
  • Cell (cell.com) — A top-tier scientific journal that publishes groundbreaking research in cell biology, often featuring studies utilizing advanced single-cell and spatial analysis techniques.
  • Briefings in Bioinformatics (academic.oup.com/bib) — Important for monitoring advancements in bioinformatics and computational biology, which are critical for analyzing the large datasets generated by 10x Genomics' platforms, especially with the rise of AI in biology.
  • BioProcess International (bioprocessintl.com) — Premier publication tracking cell culture media, downstream chromatography purification consumables, and single-use reagents from early research to biomanufacturing scale, relevant to the consumables aspect of 10x Genomics' business. [cite: Theme_Overview]

Economic Data Watch

1. PitchBook-NVCA Venture Monitor — Venture Capital Funding Data

Not in registry

Metric/field Global Biotech Venture Capital Funding (USD Billions)

Cadence quarterly

Why it matters Higher funding signals increased R&D spending by early-stage biotechs, driving demand for life science tools and services, directly impacting TXG's customer base.

Signal to watch Upward trend

Confidence: high

2. National Institutes of Health (NIH) — NIH Awards by Institute and Center / NIH RePORTER

Not in registry

Metric/field Total NIH Research Project Grants (RPGs) Funding (USD)

Cadence annual

Why it matters Direct indicator of academic research funding, which drives demand for 10x Genomics' tools in universities and academic medical centers, as government funding is a key priority.

Signal to watch Upward trend

Confidence: high

3. BEA — National Income and Product Accounts (NIPA)

Not in registryaccess=api

Metric/field A191RL1Q225SBEA

Cadence quarterly

Why it matters Broader economic health in the U.S. (Americas revenue up 6%) influences R&D budgets and overall spending capacity of customers, including biopharma and academic institutions.

Signal to watch Higher growth

Confidence: high

4. Trading Economics — China Economic Indicators

Not in registryaccess=scrape

Metric/field China Industrial Production

Cadence monthly

Why it matters Reflects economic health and manufacturing activity in China, a key APAC market where revenue was down 19% due to prior year pull-forward, influencing R&D spending capacity.

Signal to watch Higher growth

Confidence: high

5. Trading Economics — Euro Area Economic Indicators

Not in registryaccess=scrape

Metric/field Euro Area GDP Growth

Cadence quarterly

Why it matters Reflects economic health in the EMEA region, which grew 15%, indicating strong performance and influencing R&D budgets for 10x Genomics' customers.

Signal to watch Higher growth

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Study Records

Not in registry

Metric/field Number of new studies initiated (status 'Not yet recruiting' or 'Recruiting') for 'single-cell' OR 'spatial biology' OR '10x Genomics' OR 'Atera' OR 'Chromium' OR 'Xenium' OR 'Visium' OR 'Flex Apex'

Cadence daily

Why it matters Indicates the expanding pipeline and R&D activity in key therapeutic areas and technologies relevant to 10x Genomics, such as oncology, neurodegeneration, and cell therapies, which drives demand for their platforms.

Signal to watch Increasing number of studies

Confidence: high

2. USASpending.gov — Federal Contract and Grant Awards

Not in registryaccess=api

Metric/field Total award amount (USD) to academic/research institutions or biopharma companies for 'single-cell' OR 'spatial biology' OR 'genomics' OR 'AI biology'

Cadence daily

Why it matters Tracks government funding flowing into research areas that directly utilize or benefit from 10x Genomics' technologies, reflecting 'philanthropic and government funding priorities'.

Signal to watch Increasing award amounts

Confidence: medium

3. Google Trends — Search Interest Data

Not in registry

Metric/field Search interest for '10x Genomics' OR 'Atera' OR 'single-cell sequencing' OR 'spatial transcriptomics'

Cadence daily

Why it matters Provides a proxy for general market awareness and interest in 10x Genomics' company, new products like Atera, and core technologies, influencing future demand.

Signal to watch Increasing search interest

Confidence: high

4. SEC EDGAR — Company Filings (10-K, 10-Q, 8-K)

Matched (medium)alphasense_company_filings_transcripts_research · access=file · map_only

Metric/field Mentions of '10x Genomics' OR 'single-cell' OR 'spatial biology' OR 'Atera' in filings of biopharma companies or research institutions (e.g., CIKs of major customers/partners)

Cadence daily

Why it matters Indicates adoption, partnerships, or strategic investments by customers and competitors in technologies relevant to 10x Genomics, reflecting market traction and competitive landscape.

Signal to watch Increasing mentions or positive context

Confidence: medium

5. Indeed Hiring Lab — Job Postings Data

Not in registry

Metric/field Number of job postings containing 'single-cell' OR 'spatial biology' OR 'genomics' OR 'AI biology' OR '10x Genomics' by biopharma/academic employers

Cadence monthly

Why it matters Reflects R&D expansion and investment in areas leveraging 10x Genomics' technologies, indicating underlying demand for skilled personnel to utilize these platforms.

Signal to watch Increasing job postings

Confidence: medium

Paid Alt Data Watch

1. IQVIA — Medical Claims Data

Matchediqvia_medical_claims · access=file · map_only

Metric/field CPT code utilization for molecular diagnostic tests (e.g., specific codes for liquid biopsy, MRD, MCED, CGP, Alzheimer's biomarkers) that rely on NGS/spatial technologies

Cadence monthly

Why it matters Directly tracks the adoption and utilization of molecular diagnostic tests, aligning with 10x Genomics' future vision to extend technologies into clinical diagnostics and generate robust clinical evidence.

Signal to watch Increasing utilization

Confidence: high

2. YipitData — Medtech Product (Hospital/Surgical Center Purchasing)

Matchedyipitdata_hospital_purchasing_medtech_procurement · access=file · map_only

Metric/field Purchasing volume/spend for '10x Genomics' products (e.g., Chromium, Xenium, Atera consumables, instruments) by hospitals/research centers

Cadence monthly

Why it matters Provides direct insight into the sales and adoption of 10x Genomics' instruments and consumables by its core customer base, reflecting actual demand and utilization.

Signal to watch Increasing purchasing volume/spend

Confidence: high

3. Similarweb — Web Traffic & Engagement Data

Matchedsimilarweb_website_traffic_engagement · access=file · map_only

Metric/field Website traffic (unique visitors, page views) to 10xgenomics.com and key competitor websites, or specific product pages (e.g., Atera, Chromium)

Cadence monthly

Why it matters Serves as a leading indicator of customer interest, engagement, and research activity related to 10x Genomics' offerings and the broader market.

Signal to watch Increasing traffic and engagement

Confidence: high

4. Clarivate Life Sciences & Healthcare — Market Research Reports / Industry Intelligence

Matchedclarivate_life_sciences_drug_intelligence · access=file · map_only

Metric/field Market size and growth forecasts for single-cell analysis, spatial biology, and genomics tools and reagents (e.g., specific segments like 'spatial transcriptomics market')

Cadence irregular

Why it matters Provides strategic insights into the overall market trajectory for 10x Genomics' core businesses and future growth opportunities, validating their market expansion claims.

Signal to watch Upward revisions to market forecasts

Confidence: high

5. Hatched Analytics — Ticker-level KPI Feeds

Matchedhatched_analytics_ticker_level_transaction_digital_kpi_feeds · access=file · map_only

Metric/field Key Performance Indicators (KPIs) derived from proprietary transaction data for TXG or its major biopharma/academic customers, related to lab spending or research activity

Cadence monthly

Why it matters Offers granular, real-time insights into the operational performance and customer spending patterns that directly impact 10x Genomics' revenue.

Signal to watch Positive KPI trends

Confidence: medium

Search Keywords Brand Product

  • Atera platform
  • Chromium instruments
  • Visium spatial gene expression
  • Xenium spatial analysis
  • Flex Apex
  • Multiome product
  • Catalyst Research Services
  • Proteintech Genomics
  • single-cell analysis
  • spatial biology
  • multi-omics
  • AI drug discovery
  • genomic research tools
  • life science technology
  • proteomics

Search Keywords Event Phrases

  • 10x Genomics earnings
  • Atera launch
  • Proteintech Genomics acquisition

Search Keywords Policy Regulatory

  • academic research budget caps
  • NIH research grant outlays
What They Do (Plain English & Analogies)
10x Genomics creates advanced tools, including specialized instruments, chemical kits, and software, that help scientists study biological samples at an incredibly detailed level. Imagine trying to understand a bustling city. Instead of just seeing a map, 10x Genomics' technology allows researchers to zoom in and see what every individual person (cell) is doing, where they are located within a neighborhood (tissue), and how they interact. This 'zoom-in' capability, known as single-cell and spatial analysis, provides a much clearer picture of how diseases like cancer or Alzheimer's develop, and helps in finding new ways to treat them. Their newest platform, Atera, is like an even more powerful, high-resolution camera that can capture even more information across a larger area.
Very Brief History
Founded in 2012, initially as 10X Technologies, Inc., and later rebranded to 10x Genomics, Inc. in November 2014, the company is headquartered in Pleasanton, California. It quickly established itself as a leader in life science technology, pioneering single-cell analysis with its Chromium platforms. The company then expanded into spatial analysis with Visium and Xenium, and most recently launched its advanced Atera platform, further solidifying its position in cutting-edge biological research.
"Street Stereotype"
10x Genomics is generally perceived as a leading innovator in the life science tools sector, particularly in the rapidly evolving fields of single-cell and spatial biology. Investors and analysts often view it as a high-growth company with a strong pipeline of transformative technologies, such as the recently launched Atera platform, which is expected to drive significant market expansion. However, the market also closely scrutinizes the company's ability to manage the transition from older products to new ones, scale manufacturing for complex instruments, and translate strong demand into tangible revenue amidst broader macroeconomic uncertainties and academic funding constraints.
Subsidiaries On Linked In*
  • Proteintech Genomics — Acquired by 10x Genomics in June 2026 to expand proteomics capabilities. Previously a division within Proteintech Group.; LinkedIn: Proteintech Genomics
Customer Sectors & Example Clients
10x Genomics serves a diverse range of customers across various sectors. These include academic institutions, governmental organizations, biopharmaceutical companies, biotechnology companies, and academic medical centers. Specific examples of clients or partners mentioned include the Cleveland Clinic and Lausanne University Hospital, with whom 10x Genomics has partnerships to identify biomarkers in oncology. The company also engages with top biopharmaceutical companies and academic initiatives like CZI and the Arc Institute, which are focused on building virtual biology models.
New Customers / Segments They'Re Targeting
10x Genomics is actively targeting new customer segments beyond early technology adopters. They are focusing on expanding their reach within biopharma companies and academic medical centers for integrating their platforms into routine research, such as translational oncology programs. The company is also making its Atera platform accessible to researchers who may not yet own an instrument through its Catalyst Research Services, allowing them to submit samples for processing in 10x Genomics' labs. Furthermore, 10x Genomics envisions a significant long-term opportunity to extend its technologies into clinical diagnostics, particularly in oncology and autoimmunity, by generating robust clinical evidence on large patient cohorts. A key target segment also includes the rapidly growing number of biotech companies and large academic projects focused on building sophisticated virtual models of human biology using AI.
Sales Geographies And Expansion Plans
10x Genomics currently sells its products globally across several key geographies. These include the Americas, Europe, the Middle East, Africa (EMEA), China, and the broader Asia Pacific (APAC) region. Specific Asian locations mentioned include Jui Bei City, Taiwan; Shanghai, China; Singapore; and Tokyo, Japan. While the company has not disclosed specific plans to expand into entirely new geographic regions, its strategy focuses on deepening engagement within its existing markets and expanding the application of its technologies across these regions.
How Key Themes May Help/Hurt
10x Genomics is well-positioned to benefit significantly from the 'Life Sciences '24: Research Reagents & Consumables' theme. The growth in proteomics, immunology, cell biology, and drug-discovery experimentation directly expands demand for the specialized reagents and consumables integral to 10x Genomics' single-cell and spatial platforms. [cite: Theme_BullBearDetails, 1] The expansion of single-cell analysis and spatial biology, core to TXG's offerings, will increase the consumption of their proprietary sample-preparation kits and reagents. [cite: Theme_BullBearDetails, 2] The recurring nature of laboratory purchasing and the increasing throughput of experiments driven by automation will lead to sustained demand for their high-margin consumables. [cite: Theme_BullBearDetails, 3] Furthermore, the convergence of AI drug discovery with high-throughput wet-lab validation will accelerate demand for the vast amounts of experimental data generated by 10x Genomics' technologies. [cite: Theme_Overview, 10] Conversely, the company could be hurt by reduced biotechnology funding, pharmaceutical research budget cuts, or weaker academic grants, which could decrease overall experimental activity and purchasing, especially for expensive specialty reagents and exploratory research programs. [cite: Theme_BullBearDetails, 1] Competition from alternative assay methods or other suppliers could also pressure pricing and customer retention. [cite: Theme_BullBearDetails, 2] Lastly, issues such as reagent inconsistency, supply shortages, or poor experimental reproducibility could disrupt research workflows and damage supplier relationships. [cite: Theme_BullBearDetails, 3]

3 Main Long-Term Bull Details

  1. Pioneering and Leading Spatial Biology with Atera: The launch of Atera, described as a "game-changing new platform," is poised to transform biological research by enabling spatial whole transcriptome profiling with single-cell sensitivity at scale. This platform is expected to amplify and accelerate the growth of the spatial market, with an extensive roadmap including workflow automation, base-by-base spatial sequencing, and protein multi-omics, ensuring long-term innovation and market leadership.
  2. Structural Tailwinds from AI in Biology: AI is identified as a "significant and structural tailwind" for 10x Genomics. The company's single-cell and spatial technologies are uniquely positioned to provide the high-quality, high-resolution biological data essential for training AI models, which are increasingly pervasive across academic and biopharma research for target identification and drug development.
  3. Strong Multi-omics and Consumables Growth: 10x Genomics continues to drive robust growth in its consumables business, particularly with the accelerating momentum of Flex Apex in single-cell and Xenium in spatial. The company's focus on multi-omics, enhanced by the acquisition of Proteintech Genomics, provides comprehensive solutions for measuring gene expression and proteins on the same cell, catering to a growing interest in additional modalities and expanding usage across a broad range of applications.

3 Main Long-Term Bear Details

  1. Macroeconomic Headwinds and Funding Constraints: The academic funding environment remains "tenuous," with grant approvals not fully translating into purchasing activity, and persistent issues like increased oversight and staffing shortages affecting spending decisions. This challenging macro environment could continue to dampen demand for expensive instruments and consumables, impacting revenue growth.
  2. Transition Dynamics and Cannibalization Risk: The introduction of new, advanced platforms like Atera creates "transition dynamics," where customers moderate purchases of existing spatial products (Xenium and Visium) in anticipation of the new technology. While Atera is expected to ultimately drive market expansion, the timing and extent of this cannibalization could create near-to-medium term revenue fluctuations and impact the adoption rate of older platforms.
  3. Manufacturing and Scaling Challenges for New Products: Despite "extraordinary" demand for Atera, the company faces "manufacturing capacity constraints" in the near term, limiting the number of units that can be shipped. The ability to rapidly scale production for a complex, game-changing platform like Atera will be critical, and any delays or difficulties in this process could impact revenue recognition and market expectations for the platform's rollout.
Competitors And Differentiation
While specific competitors are not explicitly named in the transcript, 10x Genomics operates in the competitive single-cell and spatial biology markets. The company differentiates itself through several key aspects: its platforms deliver the highest data quality, largest scale, widest biological context, and most powerful multi-omics capabilities. The recently launched Atera platform is highlighted as a 'game-changing new platform' that provides 'step change advances' in throughput, flexibility, and sensitivity, enabling spatial whole transcriptome profiling with single-cell sensitivity at scale. The acquisition of Proteintech Genomics further strengthens its multi-omics offerings by integrating rich proteomic information alongside spatial transcriptomics. 10x Genomics also emphasizes its crucial role in enabling AI-driven biological research, positioning its tools as foundational for training high-quality, generalizable AI models.
Recent Performance & What The Market'S Focused On
In the second quarter of 2026, 10x Genomics reported revenue of $151 million, or $149.4 million excluding non-recurring settlement revenue, representing a 3% year-over-year growth on an adjusted basis. Total consumables revenue increased by 7%, driven by 3% growth in single-cell consumables and 16% growth in spatial consumables, with Xenium being the primary driver. Conversely, total instrument revenue declined by 47%, with both Chromium and spatial instrument revenues falling by 46% and 48% respectively, largely due to customers moderating purchases in anticipation of the Atera launch. Gross margin improved to 74% (excluding non-recurring items). The company raised its full-year 2026 revenue outlook to $610-$630 million. The market is intensely focused on the "extraordinary customer response" and strong early order flow for the new Atera platform, particularly its demand exceeding initial shipment expectations. Key areas of market scrutiny include the company's ability to ramp up Atera manufacturing and shipments (with 40 units expected in Q4), the ongoing transition dynamics impacting existing spatial products, the growth trajectory of Flex Apex in single-cell, and the tangible revenue impact of AI-driven demand.
Revenue Segments And Estimated Mix
  • Consumables — Mix: ~96%; Source: Q2 2026 transcript, calculated from adjusted revenue; Trend: Grew 7% YoY; Single-cell consumables grew 3% YoY, Spatial consumables grew 16% YoY with Xenium as primary driver.
  • Instruments — Mix: ~4%; Source: Q2 2026 transcript, calculated from adjusted revenue; Trend: Declined 47% YoY; Chromium instruments declined 46% YoY, Spatial instruments declined 48% YoY due to anticipation of Atera.
  • License and Royalty Revenue — Mix: n/m; Source: Q2 2026 transcript; Trend: $1.6 million in Q2 2026, non-recurring settlement revenue.
Product Brands
  • Chromium
  • Chromium Connect
  • Visium
  • Xenium
  • Atera
  • Flex Apex
  • Multiome
  • GEM-X
  • Catalyst Research Services
  • Proteintech Genomics Human Discovery Panel
Bull / Bear Details

10x Genomics is a leading life science technology company specializing in single-cell and spatial biology solutions. Its new Atera platform is poised to signifi

Thesis

10x Genomics is a leading life science technology company specializing in single-cell and spatial biology solutions. Its new Atera platform is poised to significantly expand the spatial market, driving strong future consumable pull-through. The company benefits from AI as a structural tailwind, increasing demand for high-resolution biological data. While near-term Atera manufacturing constraints and a tenuous academic funding environment present challenges, the long-term growth trajectory driven by innovative platforms and expanding applications remains compelling. (Updated: 2026-11-02)

Bull case

  • The launch of Atera, enabling spatial whole transcriptome profiling with single-cell sensitivity, has generated extraordinary customer demand and is expected to materially expand the spatial biology market. Its extensive roadmap, including workflow automation, base-by-base spatial sequencing, and protein multi-omics, positions it as a cornerstone platform for diverse research applications across major disease areas.

  • AI is a significant structural tailwind, driving pervasive demand for 10x Genomics' high-quality, large-scale single-cell and spatial biological data. The company's technologies are crucial for training AI models in drug discovery and basic science, with agentic AI also making complex data analysis more accessible to a broader scientific community.

  • Robust growth in Chromium consumable reaction volumes, particularly from accelerating Flex Apex adoption, and strong spatial consumables performance (Xenium and anticipated Atera pull-through) demonstrate recurring revenue strength. Atera's estimated mass utilization at $1.5 million to $3 million, about 2X that of Xenium, further enhances long-term consumable revenue prospects.

Bear case

  • Despite overwhelming demand, Atera's near-term shipment outlook is constrained by manufacturing capacity, limiting immediate revenue realization from booked orders to approximately 40 units for 2026. This also contributes to spatial transition dynamics, causing customers to moderate purchases of existing spatial products and leading to a modest sequential revenue step-down in Q3.

  • The academic funding environment remains challenging, with grant approvals not yet translating into increased purchasing activity due to persistent issues like increased oversight and staffing shortages for grant reviews and order processing. This ongoing "tenuous" macro environment could continue to suppress experimental activity and laboratory spending.

  • Total instrument revenue declined significantly by 47% year-over-year, with both Chromium and spatial instruments experiencing substantial drops in units sold. While partly attributed to customers moderating purchases in anticipation of Atera, this indicates potential market saturation for existing platforms or competitive pressures impacting upfront capital equipment sales.

Bull / Bear Case
Bear Case
Despite overwhelming demand for Atera, its near-term shipment outlook is constrained by manufacturing capacity, limiting immediate revenue realization to approximately 40 units for 2026. This contributes to spatial transition dynamics, causing customers to moderate purchases of existing spatial products and leading to an anticipated modest sequential revenue step-down in Q3. The academic funding environment remains challenging and tenuous, with grant approvals not yet translating into increased purchasing activity due to persistent issues like increased oversight and staffing shortages. This macro headwind could continue to suppress experimental activity and laboratory spending. Additionally, total instrument revenue declined significantly by 47% year-over-year, with both Chromium and spatial instruments experiencing substantial drops in units sold, indicating potential market saturation for existing platforms or competitive pressures.
Bull Case
10x Genomics is poised for significant growth driven by its new Atera platform, which has generated extraordinary customer demand and is expected to materially expand the spatial biology market. Atera's extensive roadmap, including workflow automation, base-by-base spatial sequencing, and protein multi-omics, positions it as a cornerstone platform for diverse research applications. Furthermore, AI is a significant structural tailwind, increasing demand for 10x Genomics' high-quality, large-scale single-cell and spatial biological data, crucial for training AI models in drug discovery. The company also demonstrates robust growth in Chromium consumable reaction volumes, particularly from Flex Apex adoption, and strong spatial consumables performance, with Atera's mass utilization estimated at 2X that of Xenium, enhancing long-term recurring revenue prospects.
More Compelling & Why
Bear. The company's valuation, with a negative trailing P/E and a forward P/E of 933.2x, alongside P/S ratios of 14-17x and EV/Revenue of 15-17x, appears stretched given its current unprofitability and near-term manufacturing constraints for its key growth driver, Atera. The strongest bear argument is the high valuation coupled with execution risk around Atera's limited shipments and the persistent 'tenuous' academic funding environment. My view would flip if the company demonstrates a clear path to sustained profitability, significantly accelerates Atera's manufacturing and shipments beyond current guidance, and provides tangible evidence of consumables pull-through justifying the premium valuation.
Key Factors5 rows
Key FactorWhy It MattersWhat To WatchWhat It SignalsWhere/How To TrackFree Alt DataPaid Alt Data
Atera Consumables Pull-Through and Utilization RateHigh consumables pull-through is essential for recurring revenue and long-term profitability, validating Atera's adoption beyond initial instrument sales. Strong utilization indicates sustained customer engagement and research activity.Management commentary on initial Atera consumables order volumes and early utilization trends from Q4 2026 placements. Atera's mass utilization is estimated at $1.5M-$3M, about 2X that of Xenium.Early indications of consumables pull-through approaching or exceeding 2X Xenium's utilization rate = bullish. Slower than anticipated consumables orders or utilization = bearish.Company's Q4 2026 earnings call and press release, expected early 2027.

[]

[]

Growth in Chromium Consumables Reaction Volumes (Flex Apex Adoption)Chromium consumables remain a core revenue driver, and robust reaction volume growth, particularly from Flex Apex, indicates expanding usage across applications and successful product transitions, offsetting instrument declines.Double-digit growth in single-cell consumable reaction volumes, driven by Flex Apex adoption. Management expects the large majority of Flex conversions to be complete by year-end 2026.Continued double-digit growth in reaction volumes and successful completion of Flex Apex transition by year-end = bullish. Deceleration in reaction volume growth or delayed Flex Apex adoption = bearish.Company's Q3 and Q4 2026 earnings calls and press releases (Q3 expected late 2026, Q4 expected early 2027).

[]

[]

Atera Instrument Shipments in Q4 2026Atera is the company's new flagship platform, expected to drive significant revenue growth and market expansion. Successful Q4 shipments are critical for meeting full-year guidance and demonstrating effective execution of the product launch.Number of Atera instruments shipped in Q4 2026. Management guided approximately 40 units for the full year 2026, with the vast majority expected in Q4.Shipments exceeding 40 units for the full year 2026 (implying strong Q4 performance) = bullish. Shipments at or below 40 units = neutral to bearish, indicating persistent manufacturing constraints.Company's Q4 2026 earnings call and press release, typically in early 2027.

[]

[]

Improvement in Academic Funding Environment and Purchasing ActivityThe academic market is a significant customer segment, currently facing a 'tenuous environment' where grant funding is approved but not flowing through to purchasing. Improvement would unlock pent-up demand.Management commentary on the flow-through of grant approvals to actual purchasing activity, and easing of issues like increased oversight or staffing shortages impacting order processing.Management indicating a material improvement in academic purchasing activity and a less tenuous funding environment = bullish. Continued 'Groundhog Day' sentiment with no change in purchasing patterns = bearish.Company's Q3 and Q4 2026 earnings calls and press releases.

1. USASpending.gov — Federal Contract Awards

Not in registryaccess=api

Metric/field Awards to 'biotechnology research' or 'genomics' related NAICS codes for academic institutions

Cadence monthly/quarterly

Why it matters Tracks actual federal spending on research, indicating if approved funds are translating into contracts.

Signal to watch Increase in contract awards to academic institutions for relevant research areas.

Confidence: medium

[]

Tangible Revenue Contribution from AI-Driven DemandAI is a significant structural tailwind, driving demand for high-quality biological data generated by 10x Genomics' platforms. Quantifiable revenue from AI applications would validate this thesis and accelerate growth.Management commentary on specific revenue contributions from tech bio companies or large academic projects explicitly focused on AI model training.Management providing more granular color and specific revenue figures tied to AI-driven demand = bullish. Continued qualitative statements without tangible metrics = neutral.Company's Q3 and Q4 2026 earnings calls and press releases.

[]

[]

Key Reported Metrics, Reratings Triggers & Results3 rows

This metric is crucial as it directly reflects the "spatial transition dynamics" and customer anticipation of Atera, which management expects to continue into Q

Last reported · 2026-11-05

Key reported metricsRerating thresholds
MetricLast periodWhy it mattersWhat's needed for reratingRerating contextEarnings date
Total Instrument Revenue YoY Growth-47%

This metric is crucial as it directly reflects the "spatial transition dynamics" and customer anticipation of Atera, which management expects to continue into Q3. A significant decline here could indicate a deeper-than-expected pause in instrument purchases.

A decline of less than -30% YoY, significantly improving from the prior period's -47% decline.

A moderation in instrument revenue decline would signal that the 'spatial transition dynamics' are less severe than feared and that demand for existing platforms is stabilizing, reducing concerns about market saturation.

Total Consumables Revenue YoY Growth7%

Consumables are high-margin and recurring, indicating platform utilization and customer engagement. Growth here signals healthy underlying demand for 10x Genomics' technologies, especially with new product adoption like Flex Apex and Xenium.

Consumables revenue growth of 10% or more YoY, accelerating from the prior period's 7% growth.

Strong consumables growth validates the high-margin recurring revenue model and platform stickiness, indicating healthy underlying demand and successful adoption of new products like Flex Apex, which is crucial for long-term value.

Total Revenue YoY Growth (excluding non-recurring settlement revenue)3%

This is the primary indicator of the company's overall financial health and growth trajectory. Meeting or exceeding the Q3 sequential step-down expectation will be crucial for investor confidence, especially given the Atera transition.

Flat or positive YoY growth (0% or higher), beating the consensus estimate of a slight decline (approx. -0.7% YoY).

Exceeding the guided sequential step-down and achieving flat or positive YoY growth would signal better-than-expected navigation of the Atera transition and macro headwinds, boosting investor confidence in the overall growth trajectory.

Key Questions

Can 10x Genomics successfully ramp up manufacturing and ship the anticipated 40 Atera instruments in Q4 2026, and what will be the initial consumables pull-thro

Can 10x Genomics successfully ramp up manufacturing and ship the anticipated 40 Atera instruments in Q4 2026, and what will be the initial consumables pull-through from these placements?

Question 2

Will the anticipated 'modest sequential step down' in Q3 revenue due to the spatial transition be within management's expectations, and will Atera instrument and initial consumable sales in Q4 sufficiently offset this transition to meet full-year guidance?

Question 3

Will the Flex Apex transition successfully drive sustained double-digit growth in Chromium consumable reaction volumes, and will 10x Genomics provide more tangible evidence of AI-driven revenue contribution in the coming quarter?

Earnings Transcript SummaryTable
· 2026Q2 Earnings Call
3 Things Management Is Most Focused OnCall Takeaway & TonePrior Quarter'S Y/Y Growth By Segment3 Things Analysts Most Pressed On (And Mgmt Responses)Revenue Segments
3 Things Management Is Most Focused On1. **Atera Launch and Customer Response**: Management is highly focused on the extraordinary customer response and strong early order flow for Atera, viewing it as the biggest highlight of the year and a platform poised to transform biological research. 2. **Sustained Strength in Core Consumables**: They emphasize robust growth in Chromium consumable reaction volumes and exceptional Xenium utilization, reflecting expanding usage and reinforcing its position in spatial analysis. 3. **Leveraging AI as a Structural Tailwind**: Management believes AI represents a significant opportunity, driving demand for high-quality biological data generated by their single-cell and spatial technologies, and making complex data analysis more accessible.Call Takeaway & ToneThe overall takeaway of the call is one of cautious optimism, with a strong focus on the transformative potential and early success of the new Atera platform. Management expressed significant enthusiasm for Atera's demand and future impact, while acknowledging near-term manufacturing constraints for its rollout. The tone was positive regarding strategic direction and product innovation, particularly with Atera and the increasing influence of AI on demand for their technologies. However, there was a cautious undertone regarding the broader macro environment and academic funding, which is expected to remain tenuous. The company is navigating a transition period with existing spatial products moderating due to Atera's anticipation, but expects a strong Q4 driven by Atera shipments.Prior Quarter'S Y/Y Growth By SegmentTotal revenue (excluding non-recurring settlement revenue): 9% YoY. Total consumables revenue: 13% YoY. Single-cell consumables revenue: 6% YoY. Spatial consumables revenue: 31% YoY. Total instrument revenue: declined 24% YoY. Chromium instrument revenue: fell 12% YoY. Spatial instrument revenue: dropped 32% YoY. Americas revenue: up 9% YoY. EMEA revenue: up 15.5% YoY. APAC revenue: up 4.4% YoY.3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Atera Manufacturing Capacity and Future Scaling**: Analysts questioned why the Atera shipment outlook remained conservative despite strong demand. Management responded that the constraint is manufacturing capacity, with efforts underway to scale up for next year and beyond, expressing optimism about future utilization. 2. **Q3 Revenue Guidance and Q4 Drivers**: Analysts asked about the modest sequential step-down in Q3 revenue guidance and the drivers for the significant Q4 step-up. Management clarified that the Q3 dynamics are consistent with prior expectations, primarily due to spatial transition, and Q4 growth is largely driven by Atera instrument shipments, supplemented by normal seasonal strength. 3. **Chromium/Single-Cell Platform Performance and AI-Driven Demand**: Analysts inquired about the softer Chromium consumable growth and instrument sales, and sought tangible metrics for AI-driven demand. Management attributed Chromium dynamics primarily to the Flex Apex transition driving robust reaction volume growth, and stated that AI is a pervasive structural tailwind, influencing most significant biological data generation efforts, though specific revenue quantification is still early.Revenue SegmentsTotal revenue (excluding non-recurring settlement revenue): 3% YoY. Total consumables revenue: 7% YoY. Single-cell consumables revenue: 3% YoY. Spatial consumables revenue: 16% YoY. Total instrument revenue: declined 47% YoY. Chromium instrument revenue: down 46% YoY. Spatial instrument revenue: down 48% YoY. Americas revenue (excluding non-recurring): up 6% YoY. EMEA revenue: grew 15% YoY. APAC revenue: down 19% YoY.
Transcript TidbitsTable
About Expanding Eligible MarketAbout CompetitionAbout The Broader IndustryWhere Things Are HeadedUpdates On ThemeBroader Themes EmergingBullish-Leaning Quotes (Short)Bearish-Leaning Quotes (Short)Hiring
About Expanding Eligible MarketThe launch of Atera is enabling spatial whole transcriptome profiling with single-cell sensitivity at scale, providing researchers with a fundamentally more complete view of biological systems and answers to many questions previously out of reach. Customer engagement spans universities, academic medical centers, and biopharma companies across nearly every major disease area, including oncology, neurodegeneration, autoimmune, inflammatory disease, cardiometabolic conditions, kidney, and transplant biology. Atera's roadmap includes workflow automation, base-by-base spatial sequencing, and the addition of protein multi-omics. The acquisition of Proteintech Genomics enhances proteomics capabilities, further expanding the biological questions Atera can address. Single-cell platforms are being adopted for larger, more ambitious studies and large-scale perturbation experiments. There is a significant opportunity to extend technologies into clinical diagnostics in the future. Atera is expected to amplify and accelerate the spatial market and drive material expansion, attracting new customers.About CompetitionXenium continues to perform exceptionally well, reinforcing its position as the leading platform for spatial analysis today. Atera delivers 'step change advances across a range of features, including throughput, Flex, and sensitivity.' Customers overwhelmingly choose 10x Genomics products because they 'deliver the highest data quality, the largest scale, the widest biological context, and the most powerful multi-omics capabilities.' The company believes its solutions are 'much more compelling than any other potential alternatives on the market.' Xenium is currently considered 'the best spatial platform right now and will keep being used.'About The Broader IndustryBroader trends are reshaping biological research and creating new opportunities. AI represents a significant and structural tailwind for the business, with enormous potential to transform biology and human health. The key bottleneck for AI-driven progress in biology is its complexity, requiring measurement at massive scale and high resolution. AI is becoming a pervasive influencer of demand across the customer base, with most significant biological data generation efforts conceived with the goal of training AI models. This shift is driven by individual scientists and top-down philanthropic and government funding priorities. In biopharma, there's rapid growth in AI-focused investments, shifting from chemistry to modeling biology at the cell and tissue level for target identification and predicting drug response. Advances in agentic AI are beginning to remove the bioinformatics expertise bottleneck, making single-cell and spatial analysis accessible to a broader community. In the academic market, while sentiment is improving and grant approvals are occurring, funding has not yet fully flowed through to purchasing activity due to a 'tenuous environment' and issues like increased oversight and staffing shortages for grant reviews and order processing.Where Things Are HeadedAtera is envisioned as a long-duration, upgradable platform with capabilities that will continue to expand over time, including workflow automation, base-by-base spatial sequencing, and protein multi-omics. The acquisition of Proteintech Genomics is a step to enhance proteomics capabilities and strengthen the Atera platform. The company anticipates a very large opportunity for its technologies over time, especially as pharma companies leverage AI to speed up drug development. There is a significant opportunity to extend technologies into clinical diagnostics in the future, with progress being made on internal efforts and new partnerships to identify biomarkers. The company expects a significant step up in the fourth quarter as Atera shipments ramp and contribute more meaningfully to revenue, with normal seasonal Q4 strength across the rest of the portfolio. Atera is expected to take up more and more of the spatial market and drive material expansion.Updates On ThemeResearchBroader Themes EmergingAI transforming biology and human health; Convergence of molecular, cell, and tissue biology; Multi-omics integration; Centralization of research processing.Bullish-Leaning Quotes (Short)The story of the quarter was the extraordinary customer response to Atera. Customer enthusiasm has only gotten stronger. The momentum we're seeing is remarkable for a platform that was completely unknown to our customers only a few months ago. AI represents a significant and structural tailwind for our business. Our products and technologies are particularly well-positioned for this opportunity. Our expectation is that Atera demand will more than make up for any diminution in the other platforms.Bearish-Leaning Quotes (Short)Q2 revenue was $149 million and grew 3% YoY. Total instrument revenue declined 47%. APAC revenue was down 19%. Our shipment outlook of approximately 40 units for the year remains unchanged as we continue ramping production. We expect this spatial transition dynamics to continue into the third quarter, resulting in a modest sequential step down for our total revenue from Q2. The environment, again, is still tenuous, and the dollars are still not flowing out, at least as far as the spending decisions are concerned.HiringThe academic market is experiencing a 'general shortage of staffing and things like that for grant reviews and order processing' which is impacting purchasing decisions.
Upcoming EventsTable
Catalyst IDEstimated TimingEstimated Date StartEstimated Date EndCatalystWhy It MattersTicker Or Theme SpecificTranscript DateSource Type
TXG_98da5d38weighted mostly towards the fourth quarter2026-10-012026-12-31Initial commercial shipments of approximately 40 Atera instruments to customers, with the vast majority expected in Q4 2026.This marks the commercial launch and initial revenue contribution from a 'game-changing new platform' with strong early order demand, expected to drive significant revenue growth and market expansion for 10x Genomics.Ticker2026-08-06earnings_transcript